News
-

Gila Monster Weight Loss Drug: The Byetta Story
Gila monster venom supplied the blueprint for exenatide, first marketed as Byetta. Semaglutide and tirzepatide are different, manufactured designs.
-

STEP 4 Trial Results: Regain After Wegovy Stops
After 20 weeks on semaglutide, people who continued lost more weight. Those switched to placebo regained weight despite continued lifestyle support; who reached that switch shapes the answer.
-

Who Discovered Epitalon? Vladimir Khavinson's Team
Vladimir Khavinson led the team behind epitalon. Its history runs from an animal pineal extract to a four-amino-acid peptide, with conflicting synthesis dates and important limits to the evidence.
-

SOUL Trial Results: Oral Semaglutide and the Heart
Over about four years, fewer people taking a daily semaglutide tablet had a heart attack, stroke or cardiovascular death than people on placebo. Here is who was in the trial, what it counted, and what it can't tell you.
-

SUSTAIN-6 Results: Ozempic's Heart and Eye Trial
The 2016 trial that checked semaglutide's heart safety found fewer major heart events than placebo, and an eye-complication signal that still shapes the label today.
-

Tirzepatide for Fatty Liver: What the Trials Show
In a phase 2 trial, liver inflammation cleared in up to 62% of people on tirzepatide versus 10% on placebo. It is still not approved for any liver disease, and the phase 3 answer is years away.
-

Flu Shot on Semaglutide: Yes, and When to Get It
Semaglutide and tirzepatide labels list no vaccine interaction. CDC's flu guidance continues vaccination after October while flu is circulating.
-

Semaglutide and Blood Pressure: How Much It Drops
In the main weight-loss trial, the top number fell about 5 points more on semaglutide than on placebo, mostly riding on weight loss. Here is what that gap looks like, who sees more of it, and when a falling reading needs a second look.
-

SURMOUNT-4 Results: What Stopping Tirzepatide Did
SURMOUNT-4 gave adults tirzepatide for 36 weeks, then switched half of them, by chance, to a look-alike placebo. Over the next year the placebo group regained much of its loss while the other half kept losing, and who made it to that switch shapes what the trial can tell you.
-

Tirzepatide and Pregnancy: What the Evidence Says
Tirzepatide is stopped once a pregnancy is recognized, and the U.S. labels set no fixed wait before trying to conceive. Europe and the UK use at least one month, and human data specific to tirzepatide are still thin.
-

Ozempic Prescribing Information, Explained
The Ozempic injection label, revised May 2026, covers three type 2 diabetes uses, a 0.25 mg to 2 mg dose ladder, the thyroid boxed warning, side-effect rates and storage. Here it is in plain words.
-

Peptide Myths: 10 Common Claims Checked
Ten things people say about peptides online, from "they're steroids" to "drug tests can't find them," graded against the studies and the rules that can actually answer them.
-

13 Questions to Ask Before Tesamorelin
A tesamorelin review turns on a short list: what you want it for, your cancer, pregnancy and pituitary history, and your blood sugar and IGF-1. Here are the questions worth bringing, and the label line or trial finding behind each.
-

Should I Take BPC-157? How a Provider Decides
Should I take BPC-157? It may be worth discussing for a specific, examined problem, but a provider first checks the injury, the gut, drug testing, cancer history, pregnancy and your other medicines.
-

SURPASS-2 Results: Tirzepatide vs Semaglutide
SURPASS-2 put 1,879 adults with type 2 diabetes on tirzepatide or semaglutide 1 mg for 40 weeks. Tirzepatide lowered blood sugar and weight more at every dose, against a semaglutide dose that is no longer Ozempic's highest.
-

Who Discovered PT-141? It Began as a Tanning Drug
PT-141 began as an accident: a University of Arizona tanning peptide caused unexpected erections in its first volunteers. Here is how that clue became bremelanotide, and what happened to its gray-market sibling.
-

Who Invented Tirzepatide? The Team Behind Mounjaro
No single person. Two academic scientists showed one molecule could act like two gut hormones, and an Eli Lilly team designed the drug that became Mounjaro and Zepbound. Here are the people, the papers and the patent.
-

Epitalon Side Effects: What Is and Isn't Known
Almost nobody has measured them. FDA's 2026 review found no clinical study of epitalon's safety in people, so the honest answer is mostly "unknown", and it helps to know exactly what that covers.
-

ESSENCE Trial Semaglutide: What the Biopsies Show
ESSENCE biopsied 800 adults with liver scarring after 72 weeks of weekly semaglutide or placebo. The results earned Wegovy a liver indication; the part of the trial that counts most is still running.
-

Exercise on Semaglutide: What the Research Shows
Exercise is part of how semaglutide was studied and labeled. What changes is how workouts feel while doses rise, and what the research says so far about fitness and strength.
Page 9 of 27 · 528 articles